By a News Reporter-Staff News Editor at VerticalNews Health& Science Ann Arbor, MI- When patients with glaucoma switched from a brand name drug to its generic counterpart, they were more likely to take their medication as directed compared to those who remained on the brand name drug, according to a study published online in Ophthalmology.
Actavis, Irish specialty pharmaceutical firm entered an abbreviated new drug application to the US Food and Drug Administration want approval to market Budesonide Extended-release Tablets, 9 mg. Earlier in February 2015, Santarus and Cosmo Technologies filed a lawsuit, under provisions of the Hatch-Waxman Act, against Actavis in the US District Cou
In July 2014, Abbott announced that it will sell its developed markets branded generics pharmaceuticals business to Mylan Inc. for 110 million shares of a newly formed publically traded entity that will combine Mylan's existing business and Abbott's developed markets pharmaceuticals business. On January 1, 2013, Abbott completed the separation of..
DUBLIN and SAN FRANCISCO, Feb. 27, 2015/ PRNewswire/ Actavis plc, a leading global specialty pharmaceutical company, and Medicines360, a nonprofit women's health pharmaceutical company, today announced the approval of LILETTA? by the U.S. Food and Drug Administration for use by women to prevent pregnancy for up to three years. Actavis and Medic
Actavis on February 24 confirmed that it has filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking approval to market Budesonide Extended- release Tablets, 9 mg. Cosmo Technologies Limited and Santarus, Inc. filed suit against Actavis on February 17, in the U.S. District Court for the District of Delaware seek
Akorn, Inc., a specialty generic pharmaceutical company, announced today that Tim Dick, Chief Financial Officer, will provide an overview and update of the Company's business at the Barclays Global Healthcare Conference on Thursday, March 12, 2015 at 10:15 a.m. EDT at the Loews Miami Beach Hotel in Miami Beach, Florida. Akorn, Inc. is a specialty
HYDERABAD: City-based Dr Reddy's Laboratories has received a letter from the United States Congress seeking certain information on increase in the prices of their generic drugs. The company said it agreed to provide such sample transactional data to the Texas AG no later than February 20, 2015. We have communicated with the California AG and are wo
Contract notice: Generic Drugs Topicals/Misc Items. This contract is divided into lots: no Deposits and Guarantees required: The contract authority reserves the right to request parent company guarantees of financial liability. Time limit for receipt of tenders or requests to participate: 14.4. 2015- 12:00 Conditions for opening tenders Date: 14.4.
Persistence Market Research is released upcoming report on title "Biosimilars Market- Global Industry Analysis and Forecast to 2020". New York, NY 02/27/2015 Biosimilars or follow-on biologics are biopharmaceutical drugs that are similar to approved biological drugs. Biosimilars are different from other generic drugs in terms of raw material
IGI Laboratories, Inc., a New Jersey based specialty generic pharmaceutical company, announced the Company will hold a conference call at 4:15 pm ET on Monday, March 2, 2015 to discuss the 4th quarter 2014 results. The Company invites you to listen to the call by dialing 1-888-346-3479. International participants should call 1-412-902-4260. Canad
The following discussion of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and the notes to those financial statements appearing elsewhere in this Annual Report on Form 10- K. This discussion contains forward-looking statements that involve significant risks and...
Patrick Lucy, chief business officer of Pfenex, will participate on a panel discussing the current state of the biosimilar industry landscape entitled The Evolving World of Biosimilars. Pfenex has used, and intends to continue to use, its Investor Relations website, as means of disclosing material non-public information and for complying with its..
On February 27, 2015, Santarus, Inc., a wholly owned subsidiary of Salix Pharmaceuticals, Ltd., and Cosmo Technologies Limited, the Company's licensor, commenced a lawsuit against generic drug maker Alvogen Pine Brook, Inc. for Alvogen's infringement of three patents listed in the U.S. Food and Drug Administration's Approved Drug Products with Ther
ALEXANDRIA, Va., Feb. 27, 2015/ PRNewswire-USNewswire/ Roughly three-quarters of pharmacists said they would feel confident or very confident substituting an interchangeable biosimilar for its branded biologic counterpart if the two products share the same nonproprietary name, according to a survey published in the Academy of Managed Care Pharmac
Janet Woodcock, had announced that the FDA was working on "establish ing consistent quality standards for all drugs, whether brand name or generic" over the past 10 years. As part of this effort, the FDA has established the Office of Pharmaceutical Quality. The OPQ is designed to "streamline FDA processes that monitor drug quality throughout the pr
This Item 7 contains forward-looking statements that involve risks and uncertainties. Please see "Forward-Looking Statements" on page ii of this Annual Report for a discussion of the uncertainties, risks and assumptions associated with these statements. The results of operations for the periods reflected herein are not necessarily indicative of res
By a News Reporter-Staff News Editor at Health& Medicine Week Ann Arbor, MI- When patients with glaucoma switched from a brand name drug to its generic counterpart, they were more likely to take their medication as directed compared to those who remained on the brand name drug, according to a study published online in Ophthalmology. Researchers a
Biosimilars have emerged as one of the most promising segment of the European pharmaceutical industry in recent years. The biosimilars segment has been experiencing a steady growth driven by patent expiration of blockbuster drugs, amenable regulatory framework, economic incentives along with favorable pricing and reimbursement policies adopted...
Glenmark Pharmaceuticals has received approval from the United States Food and Drug Administration for generic Ashiyna contraceptive tablets. It has launched these tablets in the United States market. Glenmark Generics Inc, USA, a subsidiary of Glenmark, has introduced Ashiyna extended-cycle oral contraceptive tablets, which are equivalent of Teva.
All references to years mean the relevant 12- month period ended December 31. As of February 6, 2015, we marketed 96 generic pharmaceuticals, which represent dosage variations of 29 different pharmaceutical compounds through our own Global Pharmaceuticals division; another five of our generic pharmaceuticals representing dosage variations of two...
The Bureau of Pharma Public Sector Undertakings of India under Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers has been selling quality generic medicines at affordable prices in the name of Jan Aushadhi medicines since 2008. The scheme is being revisited by expanding medicines basket. The Government is committed to ensure the..
Teva Pharmaceutical Industries Ltd. will host a live audio webcast at the Cowen& Company 35 th Annual Healthcare Conference in Boston, MA. Siggi Olafsson, President& CEO, Global Generic Medicine Group will present on Tuesday, March 3, 2015 at 8:40 AM EST. Headquartered in Israel, Teva is the world s largest generic medicines producer, leveraging
CHENGDU, China, Feb. 26, 2015/ PRNewswire/ Tianyin Pharmaceutical Inc., a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine, branded generics and active pharmaceutical ingredients, received notice on February 24, 2015 from the NYSE MKT LLC indicating that the Company is below certai
RANCHI: Two days after assuming office, new health minister Ramchandra Chandravanshi on Monday, assured the availability of generic drugs at all state-run medical stores as well as a complete overhaul of the ailing health infrastructure. Acknowledging the shortage of generic drugs in medical stores and state-run facilities, Chandravanshi said: "Hos
Lupin would leverage Acceliant's clinical trial platform for its clinical research and trials across Lupin Research programs. Ven Thangaraj, CTO of Acceliant said on this partnership: "We are proud to partner with Lupin. Speaking on the partnership, Santosh N. Nagaraj, Sales Head, Acceliant, commented: "Our collaboration with Lupin strengthens our